Anti-CO8A2/ COL8A2/ FECD functional antibody

Anti-CO8A2/ COL8A2/ FECD functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to COL8A2/COL8A2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0805-Ab-1/ GM-Tg-hg-SE0805-Ab-2Anti-Human COL8A2 monoclonal antibodyHuman
GM-Tg-rg-SE0805-Ab-1/ GM-Tg-rg-SE0805-Ab-2Anti-Rat COL8A2 monoclonal antibodyRat
GM-Tg-mg-SE0805-Ab-1/ GM-Tg-mg-SE0805-Ab-2Anti-Mouse COL8A2 monoclonal antibodyMouse
GM-Tg-cynog-SE0805-Ab-1/ GM-Tg-cynog-SE0805-Ab-2Anti-Cynomolgus/ Rhesus macaque COL8A2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0805-Ab-1/ GM-Tg-felg-SE0805-Ab-2Anti-Feline COL8A2 monoclonal antibodyFeline
GM-Tg-cang-SE0805-Ab-1/ GM-Tg-cang-SE0805-Ab-2Anti-Canine COL8A2 monoclonal antibodyCanine
GM-Tg-bovg-SE0805-Ab-1/ GM-Tg-bovg-SE0805-Ab-2Anti-Bovine COL8A2 monoclonal antibodyBovine
GM-Tg-equg-SE0805-Ab-1/ GM-Tg-equg-SE0805-Ab-2Anti-Equine COL8A2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0805-Ab-1/ GM-Tg-hg-SE0805-Ab-2; GM-Tg-rg-SE0805-Ab-1/ GM-Tg-rg-SE0805-Ab-2;
GM-Tg-mg-SE0805-Ab-1/ GM-Tg-mg-SE0805-Ab-2; GM-Tg-cynog-SE0805-Ab-1/ GM-Tg-cynog-SE0805-Ab-2;
GM-Tg-felg-SE0805-Ab-1/ GM-Tg-felg-SE0805-Ab-2; GM-Tg-cang-SE0805-Ab-1/ GM-Tg-cang-SE0805-Ab-2;
GM-Tg-bovg-SE0805-Ab-1/ GM-Tg-bovg-SE0805-Ab-2; GM-Tg-equg-SE0805-Ab-1/ GM-Tg-equg-SE0805-Ab-2
Products NameAnti-COL8A2 monoclonal antibody
Formatmab
Target NameCOL8A2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-COL8A2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0805-Ag-1Recombinant multi-species CO8A2/ COL8A2/ FECD protein


    Target information

    Target IDGM-SE0805
    Target NameCOL8A2
    Gene ID1296,329941,313592,713447,482478,101087762,539415,100069339
    Gene Symbol and SynonymsCOL8A2,FECD,FECD1,PPCD,PPCD2
    Uniprot AccessionP25067
    Uniprot Entry NameCO8A2_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000171812
    Target ClassificationN/A

    The target: COL8A2, gene name: COL8A2, also named as FECD, FECD1, PPCD, PPCD2. This gene encodes the alpha 2 chain of type VIII collagen. This protein is a major component of the basement membrane of the corneal endothelium and forms homo- or heterotrimers with alpha 1 (VIII) type collagens. Defects in this gene are associated with Fuchs endothelial corneal dystrophy and posterior polymorphous corneal dystrophy type 2. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.